Sequencing-based newborn screening could not identify all children with metabolic disorders or hearing loss, but could interrogate a larger number of conditions.
In PLOS this week: CLCA2 expression linked to survival among African-American women with aggressive breast cancer, gene alterations linked to hearing loss, and more.
The pharmacogenetic test, which runs on a platform from British company Genedrive, will be tested in two neonatal intensive care units in Manchester and Liverpool.
